Latest news
Bayer’s ESC 2026 programme puts the heart-kidney axis centre stage. Disease silos are starting to look obsolete
Bayer will bring 11 oral presentations to ESC Congress 2026 spanning chronic kidney disease, heart failure, secondary stroke prevention, cardiac amyloidosis and gene therapy. The programme reflects a broader shift in cardiology: from treating the heart, kidneys and metabolism as separate domains toward targeting the biological overlap between them.
Huntington’s Disease Gets an Oral Target-Engagement Signal
A Urine Test for Alzheimer’s Would Change the Access Conversation
AI Multiomics Moves Into the Trial Stratification Layer
A New CELMoD Raises the Bar in Relapsed Myeloma
IPM Alliance launches at the World Health Assembly in Geneva
IAPM Launches Oncology Pillar at ASCO: Closing the Gap Between Cancer Breakthroughs and Patient Access
WHA 2026: WHO resolution moves precision medicine onto the global health policy agenda
ASCO 2026: Pancreatic cancer gets its precision medicine moment
ASCO 2026: GI cancers are finally moving out of oncology’s blind spot
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.